NCT00493818View on ClinicalTrials.gov

Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693

PHASE1TerminatedINTERVENTIONAL

Enrollment

70

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Cancer

Interventions

DRUG

GSK690693

Trial Locations (3)

27710

GSK Investigational Site, Durham

46202

GSK Investigational Site, Indianapolis

48201

GSK Investigational Site, Detroit

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY